Cannabiz (Aus) report this morning..
However, it said it would continue to work with the TGA with a view to lifting the dose to 300 mg/day as “this is the threshold at which higher quality evidence accumulates around CBD efficacy, in the absence of significant safety concerns”.
MCIA chair Peter Crock added: “Down-scheduling CBD will benefit patients by allowing them to move from the illicit market and providing easier and more affordable access to high-quality products.”
While noting products will require TGA approval and inclusion on the Australian Register of Therapeutic Goods (ARTG), along with a number of other restrictions, Crock said the decision will provide a pathway for the industry to develop products for this market.
Read the full Cannabiz story and all the other industry reactions at
Industry reacts to TGA down-scheduling decision with cautious optimism
Hemp Industry Daily have also picked up on the Cannabiz story at
Australia nixes prescription requirement for select CBD products
